




International Journal of Medicine and Pharmaceutical Research

Journal Home Page: www.pharmaresearchlibrary.com/ijmpr



RESEARCH ARTICLE

Analytical Method Development and Validation for the Simultaneous Estimation of Buprenorphine and Naloxone by RP- HPLC Method

Dr. Gampa Vijay Kumar^{1*}, G. Sravanya²

¹Professor and Head, Dept. of Pharmacy, KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

²KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

ABSTRACT

High performance liquid chromatography is at present one of the most sophisticated tool of the analysis. The estimation of Buprenorphine and Naloxone was done by RP-HPLC. The Phosphate buffer was p^H 3.0 and the mobile phase was optimized with consists of Methanol: Phosphate buffer mixed in the ratio of 70:30 % v/v. Inertsil C₁₈ column C18 (4.6 x 150mm, 5µm) or equivalent chemically bonded to porous silica particles was used as stationary phase. The detection was carried out using UV detector at 260 nm. The solutions were chromatographed at a constant flow rate of 0.8 ml/min. the linearity range of Buprenorphine and Naloxone were found to be from 100-500 µg/ml of Buprenorphine and 1-5µg/ml of Naloxone. Linear regression coefficient was not more than 0.999. The values of % RSD are less than 2% indicating accuracy and precision of the method. The percentage recovery varies from 98-102% of Buprenorphine and Naloxone. LOD and LOQ were found to be within limit. The results obtained on the validation parameters met ICH and USP requirements .it inferred the method found to be simple, accurate, precise and linear. The method was found to be having suitable application in routine laboratory analysis with high degree of accuracy and precision.

Key Words: Methanol: Phosphate buffer, Inertsil C₁₈ column, Buprenorphine and Naloxone

ARTICLE INFO

Corresponding Author

Dr. Gampa Vijay Kumar

Professor and Head, Dept. of Pharmacy,
KGR Institute of Technology and Management,
Rangareddy, Telangana, India.

MS-ID: JPBMAL3761



PAPER-QR CODE

ARTICLE HISTORY: Received 11 May 2018, Accepted 19 June 2018, Available Online 18 July 2018

Copyright©2018 Dr. Gampa Vijay Kumar, et al. Production and hosting by Pharma Research Library. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Citation: Dr. Gampa Vijay Kumar, et al. Analytical Method Development and Validation for the Simultaneous Estimation of Buprenorphine and Naloxone by RP- HPLC Method. J. Pharm, Biomed. A. Lett., 2018, 6(2): 47-52.

CONTENTS

1. Introduction	48
2. Materials and Methods	48
3. Results and Discussion.	49
4. Conclusion	51
5. References	52

1. Introduction

Buprenorphine, sold under the brand name Subutex, among others, is an opioid used to treat opioid addiction, acute pain, and chronic pain. It can be used under the tongue, by injection, as a skin patch, or as an implant. For opioid addiction it is typically only started when withdrawal symptoms have begun and for the first two days of treatment under direct observation of a health care provider. For longer term treatment of addiction a combination formulation of buprenorphine/naloxone is recommended to prevent misuse by injection. Maximum pain relief is generally within an hour with effects up to 24 hours.




Fig 1: Structure of Buprenorphine

Naloxone, sold under the brandname Narcan among others, is a medication used to block the effects of opioids, especially in overdose. Naloxone may be combined with an opioid (in the same pill) to decrease the risk of misuse. When given intravenously, naloxone works within two minutes, and when injected into a muscle, it works within five minutes; it may also be sprayed into the nose. The effects of naloxone last about half an hour to an hour. Multiple doses may be required, as the duration of action of most opioids is greater than that of naloxone.




Fig 2: Structure of Naloxone

2. Materials and Methods

Chemicals

Buprenorphine and Naloxone, KH_2PO_4 , Water and Methanol for HPLC, Acetonitrile for HPLC, Ortho phosphoric Acid.

Instrumentation

HPLC Shimadzu, model No. SPD-20MA LC+20AD, Software- LC-20 Solution. UV/VIS spectrophotometer LABINDIA UV 3000+pH meter, Adwa – AD 1020 Weighing machine.

Chromatographic conditions

Column	:InertsilC18(4.6*250mm) 5 μm
Mobile phase ratio	:Phosphate buffer pH 3.0: Methanol (30:70%v/v)
Detection wavelength	: 260 nm
Flow rate	: 0.8 ml/min

Injection volume	:10 μl
Column Temperature	:Ambient
Auto sampler temp	:Ambient




Fig 3: Optimized Chromatogram Buprenorphine and Naloxone

Observation: The separation was good, peak shape was good, so we conclude that there is no required for reduce the retention times of peaks, so it is taken as final method.

Standard Solution Preparation:

Accurately weigh and transfer 10 mg of Buprenorphine and Naloxone 10mg of working standard into a 10mL & 100ml clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution). Further pipette 3ml & 0.3ml of the above stock solutions into a 10ml volumetric flask and dilute up to the mark with diluent.

Sample Solution Preparation:

Accurately weigh 10 tablets crush in mortar and pestle and transfer equivalent to 10 mg of Buprenorphine and Naloxone (marketed formulation) sample into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution). Further pipette 3 ml of Buprenorphine and Naloxone of the above stock solution into a 10ml volumetric flask and dilute up to the mark with diluent.

Method Validation

Precision: Accurately weigh and transfer 25 mg of Buprenorphine and Naloxone working standard into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Intermediate Precision/Ruggedness: To evaluate the intermediate precision (also known as Ruggedness) of the method, Precision was performed on different day by using different make column of same dimensions.

Accuracy:

Accurately weigh and transfer 10 mg of Buprenorphine and Naloxone 10mg of working standard into a 10mL & 100ml clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Linearity:

Accurately weigh 10 tablets crush in mortar and pestle and transfer equivalent to 10 mg of Buprenorphine and Naloxone (marketed formulation) sample into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Limit of Detection:

Accurately weigh and transfer 10 mg of Buprenorphine working standard into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Limit of Detection:

Accurately weigh and transfer 10mg of Naloxone working standard into a 100ml clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Limit of Quantification:

Accurately weigh and transfer 10 mg of Buprenorphine working standard into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Limit of Quantification:

Accurately weigh and transfer 10mg of Naloxone working standard into a 100mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Robustness:

As part of the Robustness, deliberate change in the Flow rate, Mobile Phase composition, Temperature Variation was made to evaluate the impact on the method.

3. Results and Discussion

Linearity:




Fig 4: Calibration graph for Buprenorphine at 260 nm




Fig 5: Calibration graph for Naloxone at 260 nm

Robustness:

Table 1: Results of system suitability parameters for Buprenorphine and Naloxone

S.No	Name	Retention time(min)	Area (µV sec)	Height (µV)	USP resolution	USP tailing	USP plate count
1	Buprenorphine	2.5	124505	213642		1.2	4673.4
2	Naloxone	3.9	1308495	154566	6.0	1.3	6090.3

The standard and samples of Buprenorphine and Naloxone were injected by changing the conditions of chromatography. There was no significant change in the parameters like resolution, tailing factor, asymmetric factor, and plate count.

Variation in Flow:




Fig 6: Chromatogram showing less flow of 0.6ml/min




Fig 7: Chromatogram showing more flow of 1.0ml/min

Mobile Phase:




Fig 8: Chromatogram showing less organic composition




Fig 9: Chromatogram showing more organic composition

Table 2: Results of method precession for Buprenorphine and Naloxone

Injection	Peak Area	
	Buprenorphine	Naloxone
Injection-1	1302729	123149
Injection-2	1302947	123766
Injection-3	1303236	124271
Injection-4	1303977	124691
Injection-5	1309759	124956
Average	1304529.8	124162.7
Standard Deviation	2961.1	725.6
%RSD	0.2	0.6

Table 3: Results of Intermediate precision for Buprenorphine and Naloxone

Injection	Peak Area	
	Buprenorphine	Naloxone
Injection-1	1300148	122487
Injection-2	1304520	122626
Injection-3	1305937	122632
Injection-4	1306476	122702
Injection-5	130871	122962
Average	1305070.2	122681.8
Standard Deviation	3061.8	174.8
%RSD	0.2	0.1

Table 4: Accuracy (recovery) data for Buprenorphine

%Concentration (at specification Level)	Area	Amount Added (mg)	Amount Found (mg)	% Recovery	Mean Recovery
50%	656659.5	5.0	5.036	100.7%	99.84%
100%	1304258	10.0	10.003	100.0%	
150%	1854608	14.4	14.224	98.780%	

Table 5: Accuracy (recovery) data for Naloxone

%Concentration (at specification Level)	Area	Amount Added (mg)	Amount Found (mg)	% Recovery	Mean Recovery
50%	65800	5.3	5.34	100.8%	100.51%
100%	124353	10	10.10	100.01%	
150%	177940	14.2	14.45	99.68%	

Table 6: Area of different concentration of Buprenorphine

S.No.	Linearity Level	Concentration	Area
1	I	100ppm	668934
2	II	200ppm	956781
3	III	300ppm	1313873
4	IV	400ppm	1563458
5	V	500ppm	1867084
Correlation Coefficient			0.999

Table 7: Area of different concentration of Naloxone

S.No	Linearity Level	Concentration	Area
1	I	1ppm	66510
2	II	2ppm	94701
3	III	3ppm	124802
4	IV	4ppm	152731
5	V	5ppm	179732
Correlation Coefficient			0.999

Table 8: Analytical performance parameters of Buprenorphine and Naloxone

Parameters	Buprenorphine	Naloxone
Slope (m)	66574	12529
Intercept (c)	53592	50245
Correlation coefficient (R ²)	0.999	0.999

Table 9: Results of LOD

Drug name	Baseline noise(μV)	Signal obtained (μV)	S/N ratio
Buprenorphine	52	152	2.9
Naloxone	52	156	3

Table 10: Results of LOQ

Drug name	Baseline noise(μV)	Signal obtained (μV)	S/N ratio
Buprenorphine	52	522	10.03
Naloxone	52	524	10.1

Table 11: Flow Rate (ml/min) data for Buprenorphine

S. No	Flow Rate (ml/min)	System Suitability Results	
		USP Plate Count	USP Tailing
1	0.6	5339.9	1.4
2	0.8	4673.4	1.3
3	1.0	5216.0	1.4

Table 12: Flow rate (ml/min) data for Naloxone

S. No	Flow Rate (ml/min)	System Suitability Results	
		USP Plate Count	USP Tailing
1	0.8	7063.3	1.3
2	1.0	6090.3	1.2
3	1.2	6998.0	1.3

Table 13: Change in Organic Composition in the Mobile Phase for Buprenorphine

S.No	Change in Organic Composition in the Mobile Phase	System Suitability Results	
		USP Plate Count	USP Tailing
1	10% less	4508.4	1.3
2	*Actual	4673.4	1.4
3	10% more	4318.1	1.3

Table 14: Change in Organic Composition in the Mobile Phase for Naloxone

S.No	Change in Organic Composition in the Mobile Phase	System Suitability Results	
		USP Plate Count	USP Tailing
1	10% less	6387.7	1.2
2	*Actual	6090.3	1.2
3	10% more	6232.5	1.2

4. Conclusion

High performance liquid chromatography is at present one of the most sophisticated tool of the analysis. The estimation of Buprenorphine and Naloxone was done by RP-HPLC. The Phosphate buffer was p^H 3.0 and the mobile phase was optimized with consists of Methanol: Phosphate buffer mixed in the ratio of 70:30 % v/ v. Inertsil C₁₈ column C₁₈ (4.6 x 150mm, 5μm) or equivalent chemically bonded to porous silica particles was used as stationary phase. The detection was carried out using UV detector at 260 nm. The solutions were chromatographed at a constant flow rate of 0.8 ml/min. the linearity range of Buprenorphine and Naloxone were found to be from 100-

500 μg/ml of Buprenorphine and 1-5μg/ml of Naloxone. Linear regression coefficient was not more than 0.999. The values of % RSD are less than 2% indicating accuracy and precision of the method. The percentage recovery varies from 98-102% of Buprenorphine and Naloxone. LOD and LOQ were found to be within limit. The results obtained on the validation parameters met ICH and USP requirements .it inferred the method found to be simple, accurate, precise and linear. The method was found to be having suitable application in routine laboratory analysis with high degree of accuracy and precision.

5. References

- [1] Katasani Damodar , Srinu Bhogineni , Bala Ramanjaneyulu , Analytical Method Development and Validation for the Simultaneous Estimation of Buprenorphine Hydrochloride and Naloxone Hydrochloride in Pharmaceutical Dosage Forms By RP-HPLC India Received 30 Sep 2011; Revised 06 Dec 2011; Accepted 14 Dec 2011.
- [2] Mostafavi A, Abedi G, Jamshidi A, Afzali D, Talebi M Development and validation of a HPLC method for the determination of buprenorphine hydrochloride, naloxone hydrochloride and noroxymorphone in a tablet formulation 2009 Feb 15;77(4):1415-9. doi: 10.101
- [3] Buprenorphine Hydrochloride. United States Pharmacopoeia 30 National Formulary 25 The Official Compendia of Standards United States Pharmacopoeial Convention. 2007.
- [4] Drugbank Open Data Drug and Drug Target Database. Version 4.1. Available from: <http://www.drugbank.ca/drugs/DB01183>. [Article in Press]
- [5] Ash JE, Budavari S, O'Neill M, Smith A, Heckelman PE, Kinneary J. The Merck Index. 12 ed. London: Pharmaceutical Press; 2009. th
- [6] Heel RC, Brogden RN, TM Speight. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. *Drugs* 1979;17:81-110. USA: Chapman and Hall; 1996.
- [7] Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. *Drugs* 1991;41:326-44.
- [8] Naloxone Hydrochloride. United States Pharmacopoeia 30– National Formulary 25. The Official Compendia of Standards. United States Pharmacopoeial Convention; 2007.
- [9] Liao CL, Lee CY, Chiu TH. Development and validation of a stability indicating HPLC method for the determination of Buprenorphine in a transdermal patch. *J Food Drug Anal* 2008, 16:1-7.